Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 205

1.

Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.

Moroz MA, Kochetkov T, Cai S, Wu J, Shamis M, Nair J, de Stanchina E, Serganova I, Schwartz GK, Banerjee D, Bertino JR, Blasberg RG.

Clin Cancer Res. 2011 Mar 1;17(5):1099-110. doi: 10.1158/1078-0432.CCR-10-1430. Epub 2011 Jan 18.

PMID:
21245090
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].

Liu X, Zhou NK, Zhang JM, Liang ZY, Zheng X.

Ai Zheng. 2006 Dec;25(12):1512-6. Chinese.

PMID:
17166377
[PubMed - indexed for MEDLINE]
3.

[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.

Munk Jensen M, Erichsen KD, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

PLoS One. 2012;7(11):e50618. doi: 10.1371/journal.pone.0050618. Epub 2012 Nov 30.

PMID:
23226334
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Björkling F, Madsen J, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2010 Sep 24;5(9):e12965. doi: 10.1371/journal.pone.0012965.

PMID:
20885974
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

BMC Cancer. 2013 Apr 1;13:168. doi: 10.1186/1471-2407-13-168.

PMID:
23548101
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC.

J Nucl Med. 2013 Mar;54(3):424-30. doi: 10.2967/jnumed.112.108456. Epub 2013 Jan 22.

PMID:
23341544
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.

Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS.

Clin Cancer Res. 2006 Aug 1;12(15):4590-7.

PMID:
16899606
[PubMed - indexed for MEDLINE]
Free Article
8.

3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.

Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO.

Cancer Res. 2003 Jul 1;63(13):3791-8.

PMID:
12839975
[PubMed - indexed for MEDLINE]
Free Article
9.

In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, Pillai R, He Q, Atadja P, Lam EW, Workman P, Vigushin DM, Aboagye EO.

Cancer Res. 2006 Aug 1;66(15):7621-9.

PMID:
16885362
[PubMed - indexed for MEDLINE]
Free Article
10.

Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.

Cullinane C, Waldeck KL, Binns D, Bogatyreva E, Bradley DP, de Jong R, McArthur GA, Hicks RJ.

Nucl Med Biol. 2014 Feb;41(2):148-54. doi: 10.1016/j.nucmedbio.2013.11.001. Epub 2013 Nov 15.

PMID:
24332383
[PubMed - indexed for MEDLINE]
11.

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Bzorek M, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2013;8(1):e53410. doi: 10.1371/journal.pone.0053410. Epub 2013 Jan 4.

PMID:
23308217
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.

Perumal M, Stronach EA, Gabra H, Aboagye EO.

Mol Imaging Biol. 2012 Dec;14(6):753-61. doi: 10.1007/s11307-012-0554-2.

PMID:
22484552
[PubMed - indexed for MEDLINE]
13.

Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model.

Lee WC, Chang CH, Ho CL, Chen LC, Wu YH, Chen JT, Wang YL, Lee TW.

J Biomed Biotechnol. 2011;2011:535902. doi: 10.1155/2011/535902. Epub 2011 Aug 16.

PMID:
21869861
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.

Wang H, Zhang J, Tian J, Qu B, Li T, Chen Y, Liu J, Wang S.

J Nucl Med. 2009 Nov;50(11):1857-64. doi: 10.2967/jnumed.109.064238. Epub 2009 Oct 16. Erratum in: J Nucl Med. 2010 Jan;51(1):167.

PMID:
19837754
[PubMed - indexed for MEDLINE]
Free Article
15.

Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.

Lee SJ, Kang HY, Kim SY, Chung JH, Oh SJ, Ryu JS, Kim SB, Kang JS, Park SK, Kim HM, Kim MH, Moon DH.

Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1436-48. doi: 10.1007/s00259-011-1802-4. Epub 2011 Apr 12.

PMID:
21484374
[PubMed - indexed for MEDLINE]
16.

Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).

Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A.

PLoS One. 2008;3(12):e3908. doi: 10.1371/journal.pone.0003908. Epub 2008 Dec 12.

PMID:
19079597
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.

Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J.

J Nucl Med. 2005 Jan;46(1):114-20.

PMID:
15632041
[PubMed - indexed for MEDLINE]
Free Article
18.

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.

Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC.

Clin Cancer Res. 2009 Jul 15;15(14):4712-21. doi: 10.1158/1078-0432.CCR-08-2635. Epub 2009 Jul 7.

PMID:
19584166
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH.

J Nucl Med. 2005 Jun;46(6):945-52.

PMID:
15937304
[PubMed - indexed for MEDLINE]
Free Article
20.

Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC.

PLoS One. 2013;8(3):e58938. doi: 10.1371/journal.pone.0058938. Epub 2013 Mar 15.

PMID:
23554961
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk